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n Myocarditis
ardiovascular magnetic resonance (CMR) has become the primary tool for noninvasive
ssessment of myocardial inflammation in patients with suspected myocarditis. The International
onsensus Group on CMR Diagnosis of Myocarditis was founded in 2006 to achieve consensus
mong CMR experts and develop recommendations on the current state-of-the-art use of CMR
or myocarditis. The recommendations include indications for CMR in patients with suspected
yocarditis, CMR protocol standards, terminology for reporting CMR findings, and diagnostic
MR criteria for myocarditis (i.e., “Lake Louise Criteria”).
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ncidence and Etiology
n this paper, myocarditis is defined as inflammation of
yocardial tissue. Myocarditis has been reported in up
o 12% of young adults presenting with sudden death
1–4) and is an important underlying etiology of other
yocardial diseases such as dilated (5) and arrhythmo-
enic right ventricular (6) cardiomyopathy. The inci-
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Infectious disease accounts for most cases in previ-
usly healthy patients typically either because of a direct
iral infection or post-viral immune-mediated reaction.
yocardial inflammation, however, also may be trig-
ered by reversible and/or irreversible toxic, ischemic, or
echanical injury, drug-related inflammation, trans-
lant rejection, or other immune reactions.
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JACC White Paper: CMR in Myocarditis April 28, 2009:1475–87athogenesis and Pathology
he pathogenetic features of myocarditis are reviewed in
etail elsewhere (7). After the initial injury, local and
ystemic immune responses activate cytokines and B cells
ith subsequent edema, additional myocyte injury, and
utoantibody production. Although the molecular and cel-
ular pathophysiology may differ between different etiolo-
ies, cellular infiltration, edema, necrosis, and (in later
tages) fibrotic scars are common features.
iagnostic Approaches to
yocarditis and Their Limitations
urrently, no single clinical or imaging finding confirms the
iagnosis of myocarditis with absolute certainty. Rather, an
ntegrated synopsis, including history, clinical assessment,
nd noninvasive test results, should be used to diagnose the
isease and guide treatment.
istory and physical exam. Although of limited specificity,
careful history and thorough clinical assessment have to
recede further diagnostic tests. Patients may appear almost
ormal, may have nonspecific symptoms, but also may
resent with features of acute myocardial infarction or heart
ailure with hemodynamic compromise. Physical exams of
atients with myocarditis are often unremarkable.
entricular functional analysis. Although many patients
ith myocarditis have regional or global wall motion ab-
ormalities (8–10), dysfunction is not specific to inflamma-
ion, and its sensitivity is limited (9,11–13). Biventricular
ysfunction in myocarditis, however, was found to be the
ain predictor of death and transplantation (14).
lectrocardiogram (ECG). The ECG findings associated
ith myocarditis may include ST-segment and T-wave
hanges, Q waves, atrioventricular block, and bundle-
ranch block. Arrhythmias such as ventricular tachycardia
nd ventricular fibrillation occur. The diagnostic value of
he ECG in myocarditis, however, is limited. Aside from a
ow specificity, either ST-segment elevation or T-wave
nversion is present as the most sensitive ECG criterion
n 50% of patients, even during the first weeks of the
isease (15).
iomarkers. Depending on the severity and time of testing
uring the course of disease, serum biomarkers of myocar-
ial injury such as creatine kinase, creatine kinase-
yocardial band, and troponin may be increased. When
resent, the magnitude of increase as well as the time to
learance is similar to that of a small- to medium-sized
yocardial infarction and indicates more severe disease.
he prevalence of an increased troponin T in biopsy-proven
yocarditis, however, is only 35% to 45% (16). miopsy. Endomyocardial biopsy (EMB) is a widely ac-
epted method for diagnosing myocarditis, based upon
istopathology, immunohistology, and molecular tech-
iques to identify viral genomes. A Joint Scientific State-
ent of several professional societies on its use in various
linical scenarios has been published (17).
Some limitations of EMB have to be considered. First,
he sensitivity of EMB is limited as the result of so-called
ampling error (18–21). Second, severe complications (per-
oration, tamponade) occur in 0.1% to 0.5%, and the overall
omplication rate is 6% (17). Third, substantial debate exists
egarding diagnostic criteria for analyzing myocardial tissue
pecimens (22). The utility of the Dallas criteria (23), with
nflammatory infiltration and associated myocyte necrosis
ncharacteristic for an ischemic event as disease markers, is
imited by poor interobserver agreement (24,25).
Immunohistochemistry has a greater sensitivity than
tandard histopathology for the diagnosis of myocarditis
26,27), and immunohistology protocols and evaluation
riteria have been proposed (10,28). Cost, availability, and
imited standardization, however, have limited the wide-
pread use of immunohistology and viral genome analysis.
inally, in adults, the recommended indications for endo-
yocardial biopsy are confined to patients with heart failure
17) and, therefore, EMB is not recommended in many
atients with myocarditis.
In summary, history, clinical exam, ECG, and serology
ave an unsatisfactory diagnostic accuracy in myocarditis.
iopsy, including immunohistochemistry, remains the
idely accepted standard, but may not be appropriate for
any patients, especially those with less severe disease.
maging Modalities Other Than CMR
detailed review of noninvasive imaging in myocarditis can
e found elsewhere (29). Ultrasound studies of the heart in
yocarditis typically are performed to visualize associated
unctional abnormalities, wall thickness, and pericardial
ffusion (8,30). The diagnostic value of echocardiography is
imited by the fact that many patients with less severe
yocarditis have a normal echocardiogram and the highly
ariable echocardiographic findings lack specificity (8).
111Indium antimyosin antibody and 67gallium nuclear
maging have been used to diagnose myocarditis (31). The
pecificity of these approaches, however, is very limited (32).
uclear medicine techniques also are hampered by the
imited availability of tracers mentioned previously, poor
patial resolution, and radiation issues. In current clinical
ractice, nuclear medicine is used only rarely to diagnose
yocarditis.
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ublished Data
he use of CMR imaging offers a unique combination of
afety, clarity of anatomical visualization, interobserver con-
istency, and quantitative accuracy. Furthermore, it allows
or the comprehensive use of a wide spectrum of diagnostic
argets, especially the modifiable inherent tissue contrast.
his modality has become a standard tool in many medical
enters and currently is considered by many to be the most
ersatile and powerful cardiovascular imaging modality.
Since the first description of T2-weighted CMR findings
n children with myocarditis by Gagliardi et al. in 1991 (33)
nd the first controlled clinical study using contrast-
nhanced CMR in 1998 (9), numerous investigators have
Table 1
Published Controlled Studies on Ca
Myocarditis
Vali
Friedrich et al., Circulation 1998 (9) Clin
Laissy et al., Chest 2002 (11) Clin
Rieker et al., Rofo 2002 (36) Clin
Laissy et al., Radiology 2005 (37)* Clin
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clin
Mahrholdt et al., Circulation 2006 (40) His
Gutberlet et al., Radiology 2008 (34)† His
Yilmaz et al., Heart 2008 (43)† His
Total
*Compared with patients with acute myocardial infarction. †Compare
for chronic myocarditis.
Table 2
Diagnostic Accuracy of LV Dysfunction as Assess
LV Dysfunction (EF 55%) Validation Sensitiv
Friedrich et al., Circulation 1998 (9) Clinical 100
Laissy et al., Chest 2002 (11) Clinical 62
Laissy et al., Radiology 2005 (37)* Clinical 46
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical 38
Gutberlet et al., Radiology 2008 (34) Histology 50
Pooled data (n  276) 54
Compared with patients with acute myocardial infarction.
EF  ejection fraction; LV  left ventricular; NPV  negative predictive value; PPV  positive predictudied the diagnostic utility of noncontrast (11,13,34) and
ontrast-enhanced (11–13,34–43) CMR in patients with
yocarditis. Results have consistently shown the clinical
easibility and high diagnostic accuracy with different
ingle-technique or combined CMR protocols. Tables 1 to
show a list of published controlled trials on CMR in
yocarditis (Table 1), and data on the diagnostic accuracy
f left ventricular (LV) dysfunction (Table 2) and of CMR
riteria for myocarditis (Table 3: individual criteria; Table 4:
ombined criteria).
Although published data on diagnostic accuracy provide
olid evidence for the use of CMR in clinical settings, it is
mportant to emphasize that most of these studies were
ingle-center reports and had a small sample size, variable
nclusion criteria, and nonuniform patient populations.
urthermore, CMR studies were performed at variable time
vascular Magnetic Resonance in
No. of Patients No. of Control Patients
19 18
20 7
11 10
24 31
25 22
87 26
48 35
55 30
289 179
atients with clinical evidence but lack of immunohistologic evidence
n Controlled Trials
Specificity (%) Accuracy (%) PPV (%) NPV (%)
100 100 100 100
100 75 100 58
62 57 37 70
100 61 100 49
63 55 65 48
76% 64% 71% 60%rdio
dation
ical
ical
ical
ical
ical
tology
tology
tology
d with ped i
ity (%)
%tive value.
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JACC White Paper: CMR in Myocarditis April 28, 2009:1475–87oints after disease onset, used different imaging diagnostic
riteria, and mostly did not include biopsy for confirmation.
Furthermore, the specificity was mostly compared with
ormal control patients or those with myocardial infarction
nd not to other heart diseases with similar clinical presen-
ation, such as acute coronary syndrome or other secondary
ardiomyopathies. Current data do not allow for a clear
efinition of the diagnostic accuracy of CMR in various
linical, histological, and immunohistochemical subgroups,
nd data from larger (multicenter) trials with standardized
rotocols comparing comprehensive CMR studies to
iopsy-derived criteria are lacking.
The prognostic value of CMR criteria for myocarditis
emains to be defined. In a small study, increased myocar-
ial early gadolinium enhancement ratio at 4 weeks after
linical onset of the disease was associated with an impaired
rognosis regarding functional recovery and symptoms after
3-year follow-up (44). Confirmative studies on the prog-
ostic value of the various parameters are required.
iagnostic Targets of CMR in Myocarditis
ifferent from other diagnostic modalities, targets for CMR
ot only include functional and morphological abnormali-
ies but also tissue pathology as diagnostic features of
yocardial inflammation.
unctional abnormalities. The CMR assessment of right
entricular and LV function is very reproducible and thus
llows for identifying, quantifying, and following even mild
unctional abnormalities, if present. In patients with more
Table 3
Overview of the Diagnostic Accuracy of Individua
Validation Sensit
Early myocardial gadolinium enhancement
Friedrich et al., Circulation 1998 (9) Clinical
Laissy et al., Chest 2002 (11) Clinical
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical
Gutberlet et al., Radiology 2008 (34) Histology
Pooled data (n  194)
T2
Rieker et al., Rofo 2002 (36) Clinical 1
Laissy et al., Chest 2002 (11) Clinical
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical
Gutberlet et al., Radiology 2008 (34) Histology
Pooled data (n  178)
Late enhancement
Rieker et al., Rofo 2002 (36) Clinical
Abdel-Aty et al., J Am Coll Cardiol 2005 (18) Clinical
Mahrholdt et al., Circulation 2006 (40) Histology
Gutberlet et al., Radiology 2008 (34) Histology
Yilmaz et al., Heart 2008 (43) Histology
Pooled data (n  336)
bbreviations as in Table 2.evere myocarditis, global LV dysfunction is frequent. It is, dowever, re-emphasized that regional or less severe LV wall
otion abnormalities have a low specificity for the under-
ying pathophysiology.
ericardial effusion. Pericardial effusion has been reported
n 32% to 57% of patients with myocarditis (45–47).
lthough not specific for myocarditis, its presence is sup-
ortive evidence for active inflammation.
Regional distribution and extent and hemodynamic sig-
ificance of pericardial effusion can be assessed by the use of
tandard short- and long-axis steady-state free precession
SSFP) images acquired for morphology and function. This
equence type has an inherent T2 sensitivity, rendering
ericardial fluid bright signal intensity (Fig. 1A). The
ifferentiation from epicardial fat (which also appears
right) is straightforward: the latter is found around coro-
ary vessels (which are embedded in the epicardial fat layer)
r in the AV groove and, in SSFP images, typically
eparated from effusion by a (single-pixel) thin chemical
hift artifact layer, that is, a fine line without signal.
urthermore, fat mostly appears with a slightly lower signal
ntensity, and effusion may have a more “deformable”
ppearance through the cardiac cycle. In T1-weighted
mages (e.g., spin-echo images) fluid has low signal inten-
ity. In phase-sensitive inversion-recovery sequences, how-
ver, it may be black or white, depending on the inversion
ime settings.
Small, physiological accumulations of pericardial fluid are
ot circumferential and may not be considered pathologic.
fluid layer that contains nonfluid components (fibrinous
ssue Criteria as Assessed in Controlled Trials
) Specificity (%) Accuracy (%) PPV (%) NPV (%)
89 86 89 84
100 89 100 70
68 74 74 75
86 72 86 63
83 78 86 70
50 76 69 100
100 59 100 39
74 79 78 81
69 67 74 60
71 70 77 63
60 52 56 50
100 71 78 62
96 96 99 81
80 49 65 44
83 51 81 38
86 68 89 53l Ti
ivity (%
84
85
80
63
74
00
45
84
67
70
45
44
95
27
35
59eposits, thrombus) is pathologic.
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April 28, 2009:1475–87 JACC White Paper: CMR in Myocarditisorphological abnormalities. A transient increase of wall
hickness during myocarditis was first described in echocar-
iography studies (48) and may serve as a supportive finding
uring follow-up. A decrease of LV mass during the course
f uncomplicated myocarditis was found to be associated
ith edema as assessed by T2-weighted CMR (49). A
ransient increase of LV volumes has been observed in the
ourse of myocarditis (9) and may also may serve as
etrospective, supportive evidence for recent myocarditis.
issue Characterization With CMR
iven the unique potential of CMR to visualize tissue
hanges, this area is of special interest. As outlined previ-
usly, expected tissue pathology in active myocarditis in-
ludes intracellular and interstitial edema, capillary leakage,
yperemia, and, in more severe cases, cellular necrosis and
ubsequent fibrosis (50).
dema. An important hallmark of inflammatory cell injury
s the increased permeability of cellular membranes.
hereas initial membrane defects are of a functional nature,
eading to Na influx and subsequent intracellular edema, a
ore severe injury allows for a net efflux of water and
ransmembranous leakage of larger molecules such as tro-
onin, eventually leading to loss of cellular functions.
T2-weighted imaging sensitively detects tissue edema
ith the long T2 of water-bound protons as the contrast-
enerating mechanism, resulting in a high signal intensity of
dematous tissue (Fig. 1C). Triple inversion recovery turbo
pin echo sequences with inversion pulses for fat and blood
uppression (51) provide excellent contrast between regional
Table 4
Overview of the Diagnostic Accuracy of Several C
Validation Sensit
T2  LGE
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical
Gutberlet et al., Radiology 2008 (34) Histology
Pooled data (n  130)
T2 and/or LGE
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical
Gutberlet et al., Radiology 2008 (34) Histology
Pooled data (n  130)
Any 1 of 3
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical 1
Gutberlet et al., Radiology 2008 (42) Histology
Pooled data (n  130)
Any 2 of 3
Abdel-Aty et al., J Am Coll Cardiol 2005 (13) Clinical
Gutberlet et al., Radiology 2008 (34) Histology
Pooled data (n  130)
GE  late gadolinium enhancement; other abbreviations as in Table 2.dema and normal myocardium because of the dual sup- bression of the fat and flowing blood signal. Double
nversion recovery sequences may provide a greater signal-
o-noise ratio and be used alternatively. Importantly, edema
n patients with myocarditis may have a global myocardial
istribution and, thus, a quantitative signal intensity analysis
f the entire myocardium may be necessary. A high diag-
ostic accuracy has been shown for this approach in acute
nflammatory or ischemic injury (13,34,52).
Regional edema visible on T2-weighted CMR images
as not observed in “borderline myocarditis” but could be
ound in 36% of patients with histologically “active myo-
arditis” as defined by the Dallas criteria (39). Thus,
egional edema may have a limited sensitivity in less severe
nflammation. Short-axis views typically provide a more
obust image quality than long axis images, although apical
lices may have to be discarded because of artifacts related to
ntraventricular blood signal.
The signal-to-noise ratio of T2-weighted images strongly
epends on sequence parameters. Particularly in patients
ith arrhythmia and other motion artifacts, image quality
ay not allow for reliable visualization or quantification of
dema. Newly developed sequences may yield a more
onsistent image quality and better diagnostic accuracy than
urrently used fast spin-echo triple inversion recovery pre-
ared protocols (53,54).
yperemia and capillary leak (myocardial early gadolinium
nhancement). Regional vasodilatation is an integral fea-
ure of tissue inflammation. The increased blood volume in
he inflamed area leads to an increased uptake of contrast
gents during the early vascular phase. Because gadolinium-
inations of Tissue Criteria
) Specificity (%) Accuracy (%) PPV (%) NPV (%)
100 69 100 61
91 48 73 44
95 56 86 50
74 81 100 85
57 52 80 25
66 62 79 43
48 75 68 100
49 67 68 65
48 70 68 76
96 85 95 79
89 73 88 63
91 78 91 69omb
ivity (%
40
17
25
88
50
60
00
81
88
76
63
67ased contrast agents distribute quickly into the interstitial
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JACC White Paper: CMR in Myocarditis April 28, 2009:1475–87pace after administration, this phase lasts for the first
inutes after the contrast bolus. Contrast-enhanced fast
pin-echo T1-weighted MR during this time can be used to
ssess experimentally induced myocardial hyperemia (55)
nd to detect muscular inflammation (56). Accordingly, the
Figure 1
Short-Axis CMR Views in a
Patient With Clinically Acute Myocarditis
A) Still frames from a cine series at end-diastole (left) and end-systole (right)
howing only very mild septal hypokinesis (arrow) with preserved ejection fraction.
mall pericardial effusion is present along the lateral segments (arrowheads). These
ndings represent 2 supportive criteria for myocarditis. (B) T1-weighted spin-echo
mages before (left) and shortly after (right) gadolinium administration with early gado-
inium accumulation in the septum (arrows). Quantitative evaluation of the signal
nhancement (skeletal-muscle normalized myocardial enhancement ratio of 4.0 or an
bsolute enhancement of 45%) is required to use information from this pulse
equence as a positive criterion. (C) (Left) T2-weighted spin-echo image with high sig-
al intensity of the septum and lateral wall (arrows). Evidence for regional edema, or a
ignal intensity ratio of 2.0 (signal intensity normalized to skeletal muscle in the
ame slice), renders T2 findings positive. (Right) Late enhancement image without
vidence for significant delay of gadolinium washout. The thin subepicardial layer of
igh signal intensity in the inferolateral region represents fat.urpose of myocardial early gadolinium enhancement ratioEGEr) is to detect an overall increased volume of gadolin-
um distribution into the intravascular and interstitial space
uring the early washout period.
The diagnostic utility of contrast-enhanced T1-
eighted imaging in patients with clinically acute and
hronic myocarditis has been shown in several studies
9,13,34,35).
Currently, fast spin-echo sequences are used, which are
ulnerable to inconsistent image quality in patients with
arying heart rate and irregular breathing patterns. New
equences to assess the early phase of gadolinium kinetics
ay overcome existing limitations of image quality.
ecrosis and fibrosis (late gadolinium enhancement [LGE]).
Myocardial LGE specifically reflects irreversible myocar-
ial injury (i.e., necrosis and fibrosis). This type of imaging
ses an inversion pulse to decrease the signal response from
ormal myocardium, thereby highlighting areas with in-
reased accumulation of gadolinium as bright regions.
In earlier stages of necrosis, gadolinium enters the cells
hrough acutely injured cell membranes (7). Hence, the
olume of distribution of gadolinium is increased (12) and
isualizes myocarditis-related necrosis (Fig. 2). After in-
ammatory clearance of necrotic regions, a mesh of fibro-
Figure 2
Late Enhancement Patterns in Myocarditis
A) Normal myocardium with no evidence of irreversible myocyte injury. (B)
egional subepicardial enhancement of the lateral wall (arrow). (C) Subepicardial
nhancement of lateral and midwall enhancement of the septal wall (arrows). (D)
iffuse subepicardial enhancement.
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April 28, 2009:1475–87 JACC White Paper: CMR in Myocarditisytes with a large interstitial component replaces formerly
iable tissue, again increasing the volume of distribution for
adolinium into this extracellular space during the late
ashout period. Thus, the late sequelae of inflammatory
issue damage also can be observed by LGE.
Microscopic (57), animal (58), and clinical (59) studies
ave confirmed the role of LGE imaging as s gold standard
or in vivo detection of irreversible myocardial injury asso-
iated with myocardial infarction. In patients with myocar-
itis, several studies have demonstrated a high specificity of
GE for the detection of such injury in myocarditis
12,13,37,38,40). The regional distribution of injury as
efined by LGE not only allows differentiating ischemic
with mandatory subendocardial involvement) from non-
schemic injury (60), but also may indicate the underlying
tiology of the nonischemic insult (61).
As a potential limitation, LGE showed a variable sensi-
ivity to detect active or chronic inflammation, depending
n the selection of patients (12,13,34,39,40,43). Using the
allas criteria, De Cobelli et al. (39) found LGE to be less
ensitive in “borderline” myocarditis (44%) than in “active”
yocarditis (84%).
One reason may be that active myocarditis may not
lways lead to large-enough regions of necrotic myocytes
o be visually detectable, given the pixel size in CMR
mages. This contrasts with the situation in ischemic
ecrosis for which LGE has been shown to be highly
ensitive. Therefore, LGE may be insensitive for the
etection of symptomatic myocarditis with limited or
onfocal irreversible injury. More studies are needed to
ddress this issue.
ombined use of tissue pathology markers. Two studies have
ompared all 3 tissue-based markers as well as various
ombinations of these. Abdel-Aty et al. (13) used combined
linical criteria for active myocarditis, whereas Gutberlet et
l. (34) assessed patients with chronic myocarditis, validated
gainst histopathological criteria of myocardial inflamma-
ion. In both studies, the approach with the best overall
iagnostic accuracy was found by the combined use of all 3
issue-based CMR parameters, with the presence of at least
positive criteria defining the CMR study as positive for
yocarditis (Tables 3 and 4).
ndications, Procedure,
nd Protocol of CMR
ndications for CMR
CMR study should only be performed if patients are
ymptomatic, if there is sufficient clinical evidence for Syocarditis, and if the CMR result will likely affect clinical
anagement. Thus, it is generally indicated in patients with
urrent or persisting symptoms, evidence for significant
yocardial injury, and suspected viral etiology. CMR is of
otential use in patients with chest pain, elevated troponin,
nd normal coronary arteries, where it was shown to identify
yocarditis in more than 30% of patients (62).
Additional indications may exist for subjects with possi-
le myocarditis being exposed to strenuous physical exercise
e.g., professional athletes) or for patients with otherwise
nexplained new ECG findings consistent with myocardi-
is, even in the absence of symptoms suggestive of myocar-
itis. Table 5 lists recommended criteria for requesting a
MR study in patients with suspected myocarditis.
he CMR Procedure
he patient should be monitored throughout the session,
ncluding ECG, blood pressure, breathing, and O2 satura-
ion. Furthermore, communication to the patient should be
nsured by the use of intercom devices. A physician trained
n cardiac resuscitation should be available. As for all cardiac
iagnostic modalities, drugs and equipment for immediate
nterventions should be within reach.
Typically, patients are examined in a supine position. A
edicated cardiac phased-array surface coil should be used to
cquire functional images. It is very important to emphasize
hat for all sequences used to analyze signal intensity
qualitatively or quantitatively), either a signal intensity
orrection algorithm or the body coil should be used. The
nhomogeneous sensitivity field of surface coils may other-
ise lead to false negative (inferolateral wall) or false
ositive (septum) results.
The coverage of the heart should allow for assessing all 17
V segments according to published recommendations
63). Images of the apex may be of insufficient image quality
nd may have to be excluded.
Published data on contrast-enhanced CMR in myocar-
itis mostly have been obtained with the use of gadolinium
adopentetate dimeglumine and, thus, recommendations
re only valid for this substance or compounds with an
quivalent pharmacokinetic profile.
he CMR Protocol
ecommended imaging parameters and detailed protocol
ecommendations are provided in the Online Appendix of
his article. CMR sequences generally will be ECG-gated
nd performed by the use of breath-hold protocols. These
ecommendations are based on the current evidence as
ublished in peer-reviewed literature as of January 2009.
ome of the currently recommended sequences have distinct
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equences during free breathing may have limited diagnostic
uality, and T2-weighted spin-echo images suffer from an
nherently low signal-to-noise ratio. Although new se-
uences are being tested for these purposes, their value and
linical role remains to be defined.
valuation of CMR Images in Suspected Myocarditis
he versatility, accuracy, and reproducibility of CMR and
he generally high expectations of referring physicians call
or a careful, responsible evaluation of all available param-
ters. Table 6 summarizes CMR findings and proposed
erminology in patients with suspected myocarditis.
dema. Myocardial edema appears as an area of high
ignal intensity in T2-weighted images (Fig. 1C, left panel).
n myocarditis, it may be regional or global. It is important
o keep in mind that, in the absence of LGE, edema reflects
eversible myocardial injury (52,64).
Regional edema can be identified visually (Fig. 1C),
lthough a quantitative assessment of the signal abnormality
eems appropriate. Evaluation software allows for verifying
dema as regions with signal intensity more than 2 standard
eviations above the mean value of normal tissue. The lower
ignal-to-noise of T2-weighted images should be consid-
red, limiting the ability to correctly identify small regions
f signal inhomogeneity. Thus, it is recommended to
onsider only areas of at least 10 adjacent pixels with high
ignal intensity as relevant. Areas with abnormally low
ignal in T2-weighted images (e.g., fibrotic scars) should
ot be used for normalization.
In myocarditis, edema may be global and thus not
ecognizable to the eye. A quantitative analysis by normal-
zing the signal intensity of the myocardium to that of
Table 5
Indications for Cardiovascular Magnetic Resonanc
New Onset or Persisting Symptoms
Suggestive of Myocarditis Plus
Evidence for
Myoca
Dyspnea
or
orthopnea
or
palpitations
or
effort intolerance/malaise
or
chest pain
Ventricula
or
new or
persistin
abnorma
or
elevated
CG  electrocardiogram.keletal muscle has been shown to allow for the detection of aglobal T2 signal abnormality. Values for the T2 ratio (for
alculation, see the Online Appendix) of more than 1.9
ndicate myocarditis (13).
Involvement of skeletal muscle in systemic inflammation
ay limit the sensitivity of a signal intensity analysis
ormalized to skeletal muscle (11) and should be taken into
onsideration in patients with evidence for ongoing myosi-
is. Future studies will have to address the diagnostic
ccuracy in different scenarios.
When analyzing signal intensity, great care should be
aken to exclude high signal of inadequately suppressed
lowly flowing cavitary blood. This should not be a problem
n visual analysis because slow flow signal would have an
pparent “subendocardial” location, whereas the T2 signal
yperintensity of myocarditis is almost always subepicardial
r transmural. The identification of skeletal muscle to
alculate myocardium to skeletal muscle ratio in the same
lice may be difficult with a fat-suppressed sequence. The
iewing of T2 images side by side with colocalized SSFP or
1-weighted images is recommended to correctly identify
keletal muscle and differentiate it from subcutaneous fat.
yperemia and capillary leakage (myocardial early gadolinium
nhancement). The EGEr is defined as an increased nor-
alized gadolinium gadopentetate dimeglumine accumula-
ion in the myocardium during the early washout period.
lthough sometimes visually appreciated (Fig. 1B), quan-
itative evaluation of myocardial EGEr is required. Normal-
zation of the signal intensity in T1-weighted images to that
f skeletal muscle may be hampered by coexisting myositis.
n patients with evidence for skeletal muscle involvement as
ndicated by a skeletal muscle signal intensity increase of
0% or higher or by a recent history of muscular pain, an
bsolute myocardial signal intensity increase between pre-
Patients With Suspected Myocarditis
t/Ongoing
jury Plus Suspected Viral Etiology
nction
nin
History of recent systemic viral
disease or previous myocarditis
or
absence of risk factors for coronary
artery disease or age 35 yrs
or
symptoms not explained by
coronary stenosis on coronary
angiogram
or
recent negative ischemic
stress teste in
Recen
rdial In
r dysfu
g ECG
lities
tropond post-gadolinium images of more than 45% should be
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April 28, 2009:1475–87 JACC White Paper: CMR in Myocarditissed as a threshold consistent with myocarditis instead of
he normalized myocardial early gadolinium enhancement
atio (11). In patients with irregular breathing patterns or
ignificant arrhythmia, image quality may be reduced or
ven be nondiagnostic.
ecrosis and fibrosis (LGE). Several patterns of LGE may be
een in patients with active myocarditis (Fig. 2). Focal signal
ncreases typically are localized to the subepicardial regions
f the LV and extend to a variable extent through the
entricular wall. The LGE may be localized in inferolateral
nd, less frequently, anteroseptal segments (Fig. 1B). How-
ver, LGE may be multifocal or diffuse in distribution (Figs.
C and 1D). As a rule, the subendocardium typically is not
nvolved in an isolated fashion, clearly distinguishing this
njury pattern from ischemia-mediated injury. In the basal
eptum, the LV outflow tract and the membraneous septum
ay mimic septal LGE in short axis images and lead to
alse-positive results. Also, a line of increased signal inten-
ity may appear in the basal septum on transverse, long-axis,
r short-axis images that may not represent pathologic LGE
ut may be related to the fusion of the right ventricular
oderator band to the right ventricular portion of the
Table 6
Proposed Terminologies for Describing CMR Fin
Normal
Edema Lack of evidence
for myocardial
edema
Patchy areas or
regions of high T2
signal intensity
indicating focal or
regional edema*
Sub
la
in
re
Hyperemia
Capillary leak
Lack of evidence
for increased
myocardial early
gadolinium
enhancement
ratio
In
Irreversible cell
injury
Lack of evidence
for regional late
gadolinium
enhancement
Patchy areas of late
gadolinium
enhancement
indicating focal injury
Sub
la
e
re
Normal
LV dysfunction Normal LV function Regional systolic
dysfunction
Pericardial
effusion
Lack of evidence
for pericardial
effusion
Small pericardial
effusion
Mo
e
To avoid misinterpretation of artifacts, areas with abnormal signal intensity should consist of at l
atio between myocardium and skeletal muscle of 2.0. ‡An increased myocardial early gadolin
nd skeletal muscle of 4.0 or an absolute myocardial enhancement of 45%.
CMR  cardiovascular magnetic resonance; LV  left ventricular.nterventricular septum. womprehensive use of CMR criteria (“Lake Louise Criteria”).
ecause of the lack of large-scale multicenter data, current
ecommendations can only reflect the experts’ best-
chievable consensus based on currently available literature.
t is important to re-emphasize that rigorous test data of the
ulse sequences evaluated against the gold standard of
yocardial biopsy in clearly defined clinical subsets of
atients are still scarce. The sensitivity and specificity as
ompared with endomyocardial biopsy for the pulse se-
uences recommended in this article are based on the
imited number of patients in controlled trials. At the
urrent time, this needs to be kept in mind when employing
MR for making the diagnosis of myocarditis.
The authors recommend the combined use of all 3 tissue
arkers. If all sequences can be performed and 2 or more of
he 3 tissue-based criteria are positive, myocardial inflam-
ation can be predicted or ruled out with a diagnostic
ccuracy of 78% (pooled data, Table 4); if only LGE
maging is performed, the diagnostic accuracy is 68%
pooled data, Table 3).
The authors acknowledge that there may be clinical
ettings that require a greater sensitivity, even if this comes
s
indings Consistent With Myocardial Inflammation
dial or septal
high T2 signal
y indicating
l edema
Transmural high T2 signal
intensity indicating
regional edema,
consistent with but not
specific for myocardial
inflammation
Global high T2 signal
intensity indicating
global edema†
d myocardial early gadolinium enhancement ratio‡
dial or septal
late gadolinium
ement indicating
l injury
Transmural late gadolinium
enhancement,
consistent with but not
specific for myocardial
inflammation
Supportive CMR Findings
Global systolic dysfunction
ly large pericardial Large pericardial effusion
without hemodynamic
relevance
Large pericardial effusion
with hemodynamic
relevance
adjacent pixels to be regarded as relevant. †Global high T2 signal is defined by a signal intensity
hancement ratio is defined by either a signal intensity enhancement ratio between myocardiumding
CMR F
epicar
yer of
tensit
giona
crease
epicar
yer of
nhanc
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east 10
ium enith a reduced specificity, or vice versa. One example may
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robability or children with suspected inflammation after
ardiac transplantation. It is re-emphasized that both refer-
ing physicians and CMR readers should use the reported
riteria as part of a comprehensive diagnostic approach,
hich also includes clinical, functional, and other informa-
ion. Table 7 summarizes the recommended diagnostic
MR criteria for myocardial inflammation.
ollow-Up of Myocarditis by CMR
he decision regarding follow-up of patients with active
yocarditis depends on the individual scenario. Anecdotal
vidence suggests that CMR studies during the first days of
yocarditis may be less sensitive than those obtained 7 days
fter clinical onset of the disease (65). This may be due to
he focal nature of early stages of the disease. Thus, in a
Table 7
Proposed Diagnostic CMR Criteria (i.e., Lake Lo
In the setting of clinically suspected myocarditis,* CMR findings are consistent wi
Regional or global myocardial SI increase in T2-weighted images.†
Increased global myocardial early gadolinium enhancement ratio between myoca
There is at least 1 focal lesion with nonischemic regional distribution in inversio
enhancement”).§
A CMR study is consistent with myocyte injury and/or scar caused by myocardial i
A repeat CMR study between 1 and 2 weeks after the initial CMR study is recomm
None of the criteria are present, but the onset of symptoms has been very rece
One of the criteria is present.
The presence of LV dysfunction or pericardial effusion provides additional, support
The clinical suspicion for active myocarditis should be based on the criteria listed in Table 5.
orrection algorithm; global signal intensity (SI) increase has to be quantified by an SI ratio o
ombination with a colocalized ischemic (including the subendocardial layer) pattern of late gadol
e obtained using a body coil or a surface coil with an effective surface coil intensity correction
yocardial enhancement of 45% is consistent with myocarditis. §Images should be obtaine
ultifocal, and involve the subepicardium. If the late gadolinium enhancement pattern clearly i
nfarction is more likely and should be reported.
Abbreviations as in Table 6.
Table 8
Summary of Recommended Components for the C
LV volume and function LV end-diastolic volume and
LV end-systolic volume and
Ejection fraction
Cardiac index
LV mass and mass index
Presence or absence of markers for
inflammatory activity and injury
T2 signal/edema (regional e
Calculated global myocardia
Myocardial late gadolinium
Conclusion On the basis of the presenc
LV dysfunction and/or pe
Recommendation for follow-up Based on clinical setting
A follow-up 4 weeks afterbbreviations as in Table 6.atient with strong clinical evidence for myocarditis yet
egative criteria in the initial CMR study, a repeat scan may
e needed to establish the diagnosis. A follow-up at least 4
eeks after the onset of disease may be useful to differentiate
ncomplicated involvement of the myocardium in a sys-
emic viral illness from a complicated course with viral
ersistence or autoimmunologic disease, as viral clearance
sually is completed within the first days after infection and
issue inflammation should not take more than 2 to 3 weeks.
ndeed, pilot data indicate a prognostic relevance of
ersisting CMR markers for inflammation at 4 weeks
fter onset (44).
eporting of CMR Results
he report for a CMR study should address the specific
uestions raised by the referring physician. In suspected
Consensus Criteria) for Myocarditis
cardial inflammation, if at least 2 of the following criteria are present:
and skeletal muscle in gadolinium-enhanced T1-weighted images.‡
very-prepared gadolinium-enhanced T1-weighted images (“late gadolinium
ation if Criterion 3 is present.
if
there is strong clinical evidence for myocardial inflammation.
idence for myocarditis.
s should be obtained using a body coil or a surface coil with an effective surface coil intensity
rdium over skeletal muscle of 2.0). If the edema is more subendocardial or transmural in
nhancement, acute myocardial infarction is more likely and should be reported. ‡Images should
m; a global SI enhancement ratio of myocardium over skeletal muscle of 4.0 or an absolute
st 5 min after gadolinium injection; foci typically exclude the subendocardial layer, are often
s myocardial infarction and is colocalized with a transmural regional edema, acute myocardial
R Study Report
e index
e index
or global T2 ratio)
gadolinium enhancement ratio
cement with nonischemic regional distribution
bsence of 2 or more criteria, considering additional evidence by the presence of
al effusion
set of symptoms may have prognostic implications and thus is recommended.uise
th myo
rdium
n reco
nflamm
ended
nt and
ive ev
†Image
f myoca
inium e
algorith
d at lea
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volum
volum
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April 28, 2009:1475–87 JACC White Paper: CMR in Myocarditisyocarditis, this will usually include the inflammatory
ctivity, LV function, and other information such as peri-
ardial effusion, cardiac index, and extent of scarring.
There was consensus that for the time being the presence
r absence of the 3 criteria, if acquired, should be reported.
he report summary should include components as listed in
able 8. The report should relate quantitative values to
ublished reference values. References may be cited as
eemed appropriate.
It is important to be aware that CMR, like myocardial
iopsy, depicts the patient’s status at one point in time and
annot characterize acute, chronic, or relapsing forms.
hese attributes are based on the clinical course rather than
Table 9
International Consensus Group on Cardiovascular
(in Alphabetical Order)
Name Institution
Hassan Abdel-Aty Franz-Volhard-Klinik, Charité University Hospital, Ber
Pauline Alakija Department of Pathology & Laboratory Medicine, Un
Anthony Aletras National Heart, Lung, and Blood Institute, Bethesda
Leslie T. Cooper Mayo Clinic College of Medicine, Rochester, Minnes
Neil Filipchuk Nuclear Cardiology and Stephenson Cardiovascular
Matthias G. Friedrich Stephenson Cardiovascular MR Centre, Calgary and
and Radiology, University of Calgary, Calgary, Albe
Matthias Gutberlet Department of Diagnostic and Interventional Radiolo
Germany
Godtfred Holmvang Massachusetts General Hospital, Harvard Medical S
Debra Isaac Department of Cardiac Sciences, University of Calga
Reinhard Kandolf Department of Molecular Pathology, University of Tu
Andreas Kumar Stephenson Cardiovascular MR Centre, Calgary, Alb
Jean-Pierre Laissy Department of Radiology, Hôpital Bichat, Paris, Fran
Peter Liu Toronto General Hospital, Max Bell Research Centre
Heiko Mahrholdt Robert-Bosch-Krankenhaus, Stuttgart, Germany
Bernhard Maisch Department of Internal Medicine and Cardiology, Ph
Sabine Pankuweit Department of Internal Medicine and Cardiology, Ph
Ian Paterson Division of Cardiology, University of Alberta, Edmont
Matthias Pauschinger Klinikum Süd, Nürnberg, Germany
Sanjay Prasad Royal Brompton Hospital, London, United Kingdom
Jeanette Schulz-Menger Franz-Volhard-Klinik, Charité University Hospital, Ber
Udo Sechtem Robert-Bosch-Krankenhaus, Stuttgart, Germany
James White London Health Sciences Centre and Division of Car
Ontario, London, Ontario, Canadamaging (or biopsy) findings. The consensus group therefore pecommends against using the terms acute, chronic, and so
n with respect to CMR findings, but rather to comment on
he presence or absence of “active” or “ongoing” inflamma-
ion.
uture Developments of CMR for Myocarditis
he CMR methodology is evolving at a rapid pace. Among
umerous interesting developments, many can be expected
o be useful for application in myocarditis. As hardware and
oil technology are improving, image quality and thus
iagnostic yield will be more consistent. But, more impor-
antly, novel approaches for characterizing tissue such as
ime-resolved assessment of gadolinium wash-out, T1 map-
gnetic Resonance in Myocarditis
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ncrease the utility of CMR.
onclusions
his work provides recommendations on the use of CMR as
art of a comprehensive diagnostic approach in patients
ith suspected myocardial inflammation. The use of CMR
ppears suitable to identify patients with significant ongoing
nflammation, which may be especially important for pa-
ients with recurrent or persisting symptoms and in patients
ith new onset heart failure.
On the basis of published data, we propose a compre-
ensive CMR protocol to determine the extent and regional
istribution of reversible and irreversible myocardial injury,
s well as to detect functional and other abnormalities.
urthermore, we suggest consensus criteria providing evi-
ence for or against myocardial inflammation based on
MR findings. We are aware that these recommendations
re based on limited data and that not all centers will be able
o apply all components of the suggested protocol. New
ardware, software, and contrast agent techniques may
ecome available to further improve diagnostic and proce-
ural efficiency of CMR in myocarditis.
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APPENDIX
or the recommended imaging parameters and detailed protocol recom-
endations, please see the online version of this article.
